Actively Recruiting
Geriatric Assessment and Technology Evaluation in Prostate Cancer
Led by University of Chicago · Updated on 2025-06-08
120
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study visits where they have give blood samples, answer survey questions, and use a wearable device. After study visits are complete, there is a 4-year follow-up period. Research team will check regular doctor visits and look at participants' medical records.
CONDITIONS
Official Title
Geriatric Assessment and Technology Evaluation in Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male patients with confirmed adenocarcinoma of the prostate without certain rare cell types
- Must have at least one metastatic lesion confirmed by scans or molecular imaging
- Age 65 years or older
- Planned to start intensified hormone therapy including androgen deprivation therapy and androgen receptor signaling inhibitor
- Able to understand and willing to sign informed consent
You will not qualify if you...
- Previous exposure to androgen deprivation therapy or androgen receptor signaling inhibitor within 12 months, except starting within 12 weeks prior to enrollment
- Surgical orchiectomy performed more than 12 weeks before metastatic diagnosis
- Previous chemotherapy for metastatic prostate cancer
- Having uncontrolled medical illnesses that are not well managed or stable
- Diagnosis of small-cell carcinoma of the prostate or brain metastasis
- Not fluent in reading or writing English or Spanish
- Female or pregnant women excluded
- Presence of implantable cardiac devices
- Limb defects that prevent wearing a smartwatch
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
o University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
C
Clinical Trials Intake
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here